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doi:10.1016/j.kjms.2011.06.026Abstract Therapy-related acute leukemia develops in patients after chemotherapy and/or
radiotherapy for a prior cancer, and most cases are acute myeloid leukemia with a much lower
frequency of acute lymphoblastic leukemia (ALL). One unique feature of these therapy-related
ALL (t-ALL) is an increased incidence of chromosome band 11q23 aberrations as compared with
de novo ALL. In adult female patients, breast cancer is the most common primary cancer.
Herein, we report the case of a 49-year-old Taiwanese lady who developed t-ALL with
t(4;11)(q21;q23) 16 months after cyclophosphamide, epirubicin, and 5-fluorouracil
chemotherapy for her breast cancer. The unusual feature is that the t-ALL was heralded 4
months ago by marrow lymphocytosis comprising atypical small lymphocytes with condensed
chromatin mimicking a B-cell chronic lymphoproliferative disorder. Retrospective studies using
additional antibodies for immunophenotyping and PCR-based clonality study for immunoglob-
ulin gene rearrangement showed that these atypical small lymphocytes shared similar features
with the leukemic blasts at the frank leukemic stage. Our results suggest that these atypical
small lymphocytes are lymphoblasts in disguise and that the clinicopathological correlations
with ancillary pathological studies are important to reach a definitive diagnosis of such an
unusual case.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.of Pathology, Chi-Mei Medical Center, 901 Chung-Hwa Road, Yung-Kang City, Tainan 710, Taiwan.
.org.tw (C.-N. Lin).
vier Taiwan LLC. All rights reserved.
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Therapy-related acute leukemia (t-AL) develops in patients
after chemotherapy and/or radiotherapy for a prior cancer,
and most cases are therapy-related acute myeloid leukemia
(t-AML) with a much lower frequency of therapy-related
acute lymphoblastic leukemia (t-ALL) [1]. The 2008 World
Health Organization classification of hematopoietic and
lymphoid neoplasms defined therapy-related myeloid
neoplasms as a unique clinical syndrome and included
t-AML, myelodysplastic syndrome, and myelodysplastic/
myeloproliferative neoplasms [2]. On the other hand, t-ALL
was not defined in the World Health Organization classifi-
cation, probably because it is very rare and the clinico-
pathological features are poorly defined. One unique
feature of these t-ALL is an increased incidence of chro-
mosome band 11q23 aberrations as compared with de novo
ALL [3,4]. Rearrangements of the MLL gene located at
chromosome band 11q23 is a hallmark of t-AL and myelo-
dysplasia that result from treatment with topoisomerase II
inhibitors, which includes anthracyclines [5e7]. Breast
cancer survivors exhibit a long-term increased risk of t-AL,
most commonly t-AML and less frequently t-ALL [8,9]. In
adult females with secondary ALL, breast cancer is the
most common primary cancer, irrespectively of with or
without prior anti-cancer treatment [3]. Herein, we report
the case of a lady who developed frank t-ALL with
t(4;11)(q21;q23) 16 months after cyclophosphamide, epi-
rubicin, and 5-fluorouracil (CEF) chemotherapy for her
breast cancer. The unusual feature is that the t-ALL was
heralded 4 months ago by marrow lymphocytosis comprising
atypical small lymphocytes with condensed chromatin
mimicking a B-cell chronic lymphoproliferative disorder
(B-LPD). Retrospective studies using immunophenotyping
and clonality study for immunoglobulin gene rearrange-
ment showed that these atypical small lymphocytes shared
similar features with the leukemic blasts at the overt
leukemic stage and suggested that the earliest t-ALL was
present 4 months before the full-blown disease.
Case presentation
A 49-year-old Taiwanese woman was admitted in February
2009 with the chief complaints of general weakness, poor
appetite, and dizziness. Tracing back her history, she was
diagnosed with invasive ductal carcinoma of the left breast
and underwent modified radial mastectomy and axillary
lymph node dissection 11 months ago in March 2008. Staging
results revealed a Stage IIA disease (T2N0M0) and she
received six cycles of CEF chemotherapy without radiation.
At admission, there was no fever, chillness, or ecchymosis.
Physical examination revealed no lymphadenopathy, skin
rash, or petechia. Chest X-ray was negative for any mass
lesion or mediastinal lymphadenopathy. Hemogram showed
pancytopenia with hemoglobin level at 4.2 g/dL, a white
blood cell (WBC) count at 1,600/mL (band 0%, segment 14%,
lymphocyte 84%, atypical lymphocyte 2%, monocyte 0%,
eosinophil 0%, basophil 0%), and a platelet count at 10,000/
mL. First bone marrow (BM) aspiration and biopsy in March
2009 revealed marrow lymphocytosis.Subsequent hemogram on April 20, 2009 showed persis-
tent anemia (hemoglobin level at 11.9 g/dL) and leukocy-
tosis with numerous blasts (WBC count at 47,100/mL with
87% blasts). She received daily oral cyclophosphamide
and prednisolone (100 mg and 15 mg, respectively) with
a temporary control of leukocytosis but pancytopenia
developed later. She was readmitted in the middle of July
2009 because of fever and pancytopenia with increased
blasts (WBC count at 1,200/mL with 38% blasts). Second BM
aspiration and biopsy revealed a pro B-cell ALL. The patient
received hyperfractionated cyclophosphamide, vincristine,
doxorubicin, dexamethasone, cytarabine, and metho-
trexate chemotherapy in late July. Unfortunately, her
general condition deteriorated with pneumonia, septic
shock, and multiple organ failure, and she passed away
on August 13, 2009, 5 months after the initial presentation
of atypical marrow lymphocytosis. An autopsy was not
performed.
The first BM biopsy was hypercellular with 70% cellularity
and an increased number of small lymphocytes accounting
for 70% of marrow cells (Fig. 1AeC). The proliferation
fraction was low at less than 10% by MIB1 (Ki-67) immuno-
histochemistry. Flow cytometric immunophenotyping using
a B-LPD panel showed that these small lymphocytes
expressed CD19, CD38, CD43, and cytoplasmic CD79a
(cCD79a) but not CD3, CD5, CD20, cCD22, or CD23. Cyto-
genetic study was not performed. The second BM biopsy
revealed 100% cellularity and the marrow was near totally
replaced by blasts expressing CD43, cCD79a, IgM, and
terminal deoxynucleotidyl transferase (TdT) with focal
and weak expression of CD7 by immunohistochemistry
(Fig. 1DeF). The proliferation index was 70%. The blasts did
not express CD3, CD10, CD15, CD20, CD34, IgD, or cyclin D1.
Flow cytometry of the marrow aspirate showed a pheno-
type of CD10 CD15þ CD19þ CD20 cCD22 CD43þ cCD79aþ
TdTþ and immunoglobulin light chain (surface and
cytoplasmic). These findings indicated B-lineage ALL at
pro-B cell stage. The karyotype was 47,XX,t(4;11)(q21;q23)
[cp7]/46,XX[cp13] (Fig. 2).
Retrospective review of the first BM aspirate showed
a small amount of immature cells (around 10%) in a back-
ground of small lymphocytes, and additional immunohis-
tochemical stain with anti-TdT revealed scattered positive
cells (Fig. 1C). Additional antibodies were added for flow
cytometric study using the thawed specimen from the first
BM aspiration. The gated cells in both the first and second
marrow aspirates shared the phenotype of CD3 CD5
CD10 CD19þ CD20 cCD22 CD23 CD33þ CD38þ cCD79aþ
and HLA-DRþ. The first specimen differed from the second
by the absence of CD34 and TdT expression, and further-
more, only one-fourth of the gated cells in the first sample
expressed CD15, whereas the expression in the second
sample was more extensive (Fig. 3). Clonality study using
BIOMED-2 DH-JH primers showed two distinct clonal bands
of the same size in both specimens (Fig. 4). Although
morphologically the tumor cells in the first specimen was
small with condensed chromatin in contrast to the
medium-sized blasts in the second specimen, the immu-
nophenotype and clonality study suggested that the tumor
cells in both specimens were probably of the same clonal
origin.
Figure 1. Photomicrographs of the (AeC) first and (DeF) second marrow aspiration and biopsy in March and July 2009,
respectively. (A) In the first marrow aspirate, there are many small lymphocytes with occasional immature cells indicated by arrows
(Liu stain; 1,000). (B) The marrow biopsy shows diffuse infiltration by small lymphocytes [hematoxylin and eosin (HE) stain, 400]
and (C) scattered TdT-positive cells are highlighted (immunohistochemical stain, 400). (D) In contrast, in the second aspirate, the
marrow is filled with numerous blasts (Liu stain; 1,000). (E and F) Biopsy shows sheets of blasts (HE stain, 400) expressing TdT
(immunohistochemical stain, 400).
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Our case is a t-ALL at pro-B stage with t(4;11)(q21;q23)
after CEF chemotherapy for breast cancer. The latency
period and cytogenetic findings are typical for t-ALL after
alkylating agent and anthracycline, a topoisomerase II
inhibitor [3,10e12]. Interestingly, the unique feature is the
presence of atypical marrow lymphocytosis at 12 months
with progression to overt pro-B ALL 4 months later. Marrow
lymphocytosis in our patient may indicate a coexisting
but previously unrecognized B-LPD, B-lymphocyte precur-
sors (hematogones), or leukemic blasts with atypical
morphology mimicking small lymphocytes.
The possibility of a B-LPD in our patient is not likely as
there was no lymphocytosis in the peripheral blood and
there was no monoclonal gammopathy in the serum tosuggest lymphoplasmacytic lymphoma. Furthermore, the
same clonal bands persisted in the second biopsy when
there was no residual marrow lymphocytosis. Hematogones
may mimic lymphoblasts both morphologically and immu-
nophenotypically, and they often pose a diagnostic chal-
lenge particularly in patients with precursor B-cell ALL
after chemotherapy. Reactive lymphocytosis admixed
with hematogones may occur in patients with infections,
lymphoma, marrow regenerative states, immune cytope-
nias, and acquired immunodeficiency syndrome or other
unknown etiologies [13,14]. Immunophenotypically, hema-
togones express CD10 and always exhibit a typical complex
spectrum of antigen expression that defines the normal
antigenic evolution of B-cell precursors and lack aberrant
antigen expression. On the other hand, lymphoblasts show
maturation arrest and exhibit incomplete maturation and
Figure 2. Cytogenetic study of the bone marrow with G-banding shows reciprocal translocation involving chromosomes 4q21 and
11q23, t(4;11)(q21;q23).
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from the normal, continuous, and complete B-lineage
maturation spectrum observed for hematogones [13]. In
our case, the atypical marrow lymphocytosis in the first
aspirate aberrantly expressed myeloid markers (CD15
and CD33) but not CD10, excluding the possibility of
hematogones.
Marrow lymphocytosis was reported in patients with
precursor B-cell ALL after induction chemotherapy, and the
evolution of these patients to frank leukemic relapse inFigure 3. Flow cytometric immunophenotyping of the first (up
gated cells in both specimens share the same phenotype (CD10
negative for both surface CD34 and nuclear TdT, and furthermore,
CD15, whereas the expression in the second sample was more exten
PerCPZ peridinin chlorophyll protein.a short time along with disappearance of marrow lympho-
cytosis indicated that these lymphocytes might be
lymphoblasts in disguise [15]. In retrospect, in our patient,
a minor component of immature cells suggesting blasts
were present among a background of numerous small
lymphocytes in the first BM aspiration/biopsy, and these
immature cells probably corresponded to the scattered
TdT-positive cells by immunohistochemistry. Furthermore,
these small lymphocytes were phenotypically similar to
the blasts in the frank leukemia by flow cytometricper panels) and second (lower panels) marrow aspirates. The
CD13 CD19þ) except that the cells in the first specimen are
only one-fourth of the gated cells in the first sample expressed
sive. cCDZ cytoplasmic CD; FITCZ fluorescein isothiocyanate;
Figure 4. Polyacrylamide gel electrophoresis for clonality
study using polymerase chain reaction method with BIODED-2
primers directed for immunoglobulin heavy chain gene rear-
rangement (DH-JH) shows the same clonal band patterns
between the first and second bone marrow biopsies, indicating
that the same tumor clone is present in both specimens.
MZmolecular size marker with the brightest band at 125 base
pairs; NZ negative control (water); PZ positive control;
PoZ polyclonal control.
t-ALL as atypical marrow lymphocytosis 177immunophenotyping. We concluded that these atypical
marrow lymphocytes were probably lymphoblasts with
atypical morphology, and that clinicopathological correla-
tion with ancillary pathological studies are important to
reach a definitive diagnosis of such an unusual case.
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